A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

UCB Biopharma SRL22 enrolled

Overview

The purpose of the study is to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies and safety of CZP across the course of pregnancy in study participants with chronic inflammatory diseases.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Rheumatoid Arthritis Psoriatic Arthritis Crohn's Disease Axial Spondyloarthritis Plaque Psoriasis

Interventions

Pharmacokinetics of certolizumab pegolDRUG

The collection of blood samples for pharmacokinetics (PK) is considered interventional. Blood samples will be drawn at enrollment, predose every 4 weeks (Q4W), postdose every 8 weeks (Q8W) and postpartum predose and postdose. Study participants will be responsible for obtaining and administering commercially available approved dosing regimens of certolizumab pegol (CZP) as prescribed by each study participant's own physician.

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participant is pregnant and ≤10 weeks gestation at the time of enrollment * Participant must have been on stable, maintenance dose certolizumab pegol (CZP) treatment for at least 12 weeks independent of and prior to being enrolled in this study, for an approved indication in accordance with her treating physician * Participant expects to continue CZP therapy throughout pregnancy and for at least 12 weeks postpartum * Participant has a negative interferon gamma release assay (IGRA) or tuberculin skin test (TST) within the prior 6 months, and there has been no change in the study participant's clinical status, or social, family, or travel history. Participants with documented Bacillus Calmette-Guérin (BCG) vaccine and at low risk for tuberculosis (TB) may enroll without having a TB test performed Exclusion Criteria: * Participant has any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the study participant's ability to participate in this study * Participant is not permitted to enroll into the study if she meets any of the following TB exclusion criteria: 1. Known active TB disease 2. History of active TB involving any organ system 3. Latent TB infection 4. High risk of acquiring TB infection 5. Current nontuberculous mycobacterial (NTM) infection or history of NTM infection (unless proven to be fully recovered) * Study participant is taking a prohibited medication or has taken a prohibited medication * Live vaccine(s) within 1 month prior to Screening, or plans to receive such vaccines during the study * Study participant has any clinically significant pregnancy-related clinical or test abnormality, as judged by the investigator * Study participant had a positive or indeterminate interferon gamma release assay (IGRA) or tuberculin skin test (TST) at Screening. In case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the study participant

Locations (9)

Up0085 104

Minneapolis, Minnesota, United States

Up0085 103

Durham, North Carolina, United States

Up0085 101

Oklahoma City, Oklahoma, United States

Up0085 500

Paris, France

Outcomes

Primary Outcomes

Predose and Postdose Plasma Certolizumab Pegol (CZP) Concentrations in Women During Pregnancy, Relative to Postpartum

Predose and postdose plasma CZP concentrations in women during pregnancy, relative to postpartum, were measured. The trimesters were defined as follows: Trimester 1=up to 12 weeks and 6 days gestation, trimester 2=13-28 weeks and 6 days gestation, and trimester 3=any time at or after 29 weeks gestation.

Time frame: Predose and postdose CZP concentrations in Pregnancy trimester 1,2,3 (up to 40 weeks) and Postpartum (up to 13 weeks after delivery)

Secondary Outcomes

Number of Participants With Anti-certolizumab Pegol (CZP) Positive Antibodies Throughout the Study Period

Antibodies to CZP were evaluated in plasma samples collected from all participants throughout the study. Anti-CZP antibodies (ADAb) were measured using a three-tiered assay approach: screening, confirmatory and titration assay. Samples that were confirmed as positive in the screening and confirmatory assay were evaluated in a titration assay to quantify the ADAb level and were reported as titer (reciprocal dilution factor including minimum required dilution \[MRD\]). Sample values that were 'positive screen' and 'positive immunodepletion' were defined as ADAb positive. Once determined positive, a study participant's highest titer was used to categorize ("titer classification") the study participant as follows: Positive less than or equal to (=)32, Positive greater than (\>)32 - =128, Positive \>128 - =512, Positive \>512 - =1024, Positive \>1024 - =4096, and Positive \>4096.

Time frame: From Enrollment to Safety Follow-up (Duration of pregnancy (up to 40 weeks) + 18 weeks) (up to 58 weeks)

Percentage of Participants With Adverse Events From Time of Informed Consent (Screening) Through Safety Follow-up (SFU)

An adverse event (AE) was any untoward medical occurrence in a patient or clinical participant, temporally associated with the use of CZP, whether or not considered related to CZP.

Time frame: From Screening to Safety Follow-up (Duration of pregnancy (up to 40 weeks) + 18 weeks) (up to 58 weeks)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.